Sonja van Weely

4.0k total citations · 3 hit papers
37 papers, 3.1k citations indexed

About

Sonja van Weely is a scholar working on Physiology, Organic Chemistry and Molecular Biology. According to data from OpenAlex, Sonja van Weely has authored 37 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Physiology, 20 papers in Organic Chemistry and 16 papers in Molecular Biology. Recurrent topics in Sonja van Weely's work include Lysosomal Storage Disorders Research (27 papers), Carbohydrate Chemistry and Synthesis (20 papers) and Glycosylation and Glycoproteins Research (8 papers). Sonja van Weely is often cited by papers focused on Lysosomal Storage Disorders Research (27 papers), Carbohydrate Chemistry and Synthesis (20 papers) and Glycosylation and Glycoproteins Research (8 papers). Sonja van Weely collaborates with scholars based in Netherlands, United States and Portugal. Sonja van Weely's co-authors include Johannes M. F. G. Aerts, Carla E. M. Hollak, M. H. van Oers, Deborah Elstein, Ari Zimran, Ron A. Wevers, Wim J. Kleijer, Ben J. H. M. Poorthuis, Frances M. Platt and Raymond A. Dwek and has published in prestigious journals such as The Lancet, Journal of Clinical Investigation and Blood.

In The Last Decade

Sonja van Weely

37 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease.

1994 740 citations Carla E. M. Hollak, Sonja van Weely et al. profile →
Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis

2000 592 citations Timothy M. Cox, Robin Lachmann et al. The Lancet profile →
The frequency of lysosomal storage diseases in The Netherlands

1999 522 citations Ben J. H. M. Poorthuis, Ron A. Wevers et al. Human Genetics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sonja van Weely Netherlands	22	2.4k	1.3k	1.1k	975	890	37	3.1k
Martin Hřebı́ček Czechia	18	1.2k 0.5×	1.0k 0.8×	515 0.5×	497 0.5×	499 0.6×	39	2.2k
J. A. Lowden Canada	25	1.3k 0.5×	1.2k 0.9×	488 0.5×	301 0.3×	418 0.5×	77	2.3k
Rodney E. Infante United States	17	1.1k 0.5×	946 0.7×	247 0.2×	312 0.3×	542 0.6×	30	2.2k
Tim Edmunds United States	21	765 0.3×	972 0.7×	336 0.3×	218 0.2×	419 0.5×	35	1.8k
Jerry N. Thompson United States	15	902 0.4×	533 0.4×	249 0.2×	431 0.4×	268 0.3×	39	1.6k
Patricie Burda Switzerland	27	388 0.2×	2.1k 1.6×	693 0.6×	316 0.3×	794 0.9×	44	2.8k
Lina Abi-Mosleh United States	9	876 0.4×	800 0.6×	220 0.2×	235 0.2×	402 0.5×	9	1.7k
A Kaplan United States	18	720 0.3×	714 0.5×	253 0.2×	96 0.1×	410 0.5×	22	1.8k
A L Miller United States	23	566 0.2×	614 0.5×	242 0.2×	96 0.1×	454 0.5×	70	1.7k
Saule Naureckiene United States	9	618 0.3×	400 0.3×	227 0.2×	135 0.1×	207 0.2×	12	1.1k

Countries citing papers authored by Sonja van Weely

Since Specialization

Citations

This map shows the geographic impact of Sonja van Weely's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sonja van Weely with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sonja van Weely more than expected).

Fields of papers citing papers by Sonja van Weely

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sonja van Weely. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sonja van Weely. The network helps show where Sonja van Weely may publish in the future.

Co-authorship network of co-authors of Sonja van Weely

This figure shows the co-authorship network connecting the top 25 collaborators of Sonja van Weely. A scholar is included among the top collaborators of Sonja van Weely based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sonja van Weely. Sonja van Weely is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Leufkens, Hubert G.M., et al.. (2024). Stimulating development of innovative medicines in the European Union: does a new definition for unmet medical need add value?. Drug Discovery Today. 30(1). 104251–104251. 1 indexed citations

Sijmons, Rolf H., Dick Lindhout, Ans T. van der Ploeg, et al.. (2013). A New Coding System for Metabolic Disorders Demonstrates Gaps in the International Disease Classifications ICD-10 and SNOMED-CT, Which Can Be Barriers to Genotype-Phenotype Data Sharing. Human Mutation. 34(7). 967–973. 7 indexed citations

Moors, Ellen H.M., et al.. (2011). Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe?. Orphanet Journal of Rare Diseases. 6(1). 59–59. 9 indexed citations

Heitner, René, Deborah Elstein, Johannes M. F. G. Aerts, Sonja van Weely, & Ari Zimran. (2002). Low-Dose N-Butyldeoxynojirimycin (OGT 918) for Type I Gaucher Disease. Blood Cells Molecules and Diseases. 28(2). 127–133. 79 indexed citations

Cox, Timothy M., Robin Lachmann, C. E. Hollak, et al.. (2000). Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. The Lancet. 355(9214). 1481–1485. 592 indexed citations breakdown →

Aerts, Johannes M. F. G., Rolf G. Boot, Edward F. C. Blommaart, et al.. (1999). Chitotriosidase: applications and features of the enzyme. Pure Amsterdam UMC. 4 indexed citations

Poorthuis, Ben J. H. M., Ron A. Wevers, Wim J. Kleijer, et al.. (1999). The frequency of lysosomal storage diseases in The Netherlands. Human Genetics. 105(1-2). 151–156. 522 indexed citations breakdown →

Dahl, Stephan vom, K. Harzer, Arndt Rolfs, et al.. (1999). Hepatosplenomegalic lipidosis: what unless Gaucher? Adult cholesteryl ester storage disease (CESD) with anemia, mesenteric lipodystrophy, increased plasma chitotriosidase activity and a homozygous lysosomal acid lipase −1 exon 8 splice junction mutation. Journal of Hepatology. 31(4). 741–746. 46 indexed citations

Boot, Rolf G., Carla E. M. Hollak, Marri Verhoek, et al.. (1997). Glucocerebrosidase genotype of Gaucher patients in The Netherlands: Limitations in prognostic value. Human Mutation. 10(5). 348–358. 34 indexed citations

10.

Michelakakis, Helen, et al.. (1996). Plasma tumor necrosis factor-a (TNF-a) levels in Gaucher disease. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1317(3). 219–222. 82 indexed citations

11.

Bijsterbosch, Martin K., et al.. (1996). Quantitative Analysis of the Targeting of Mannose‐Terminal Glucocerebrosidase. European Journal of Biochemistry. 237(2). 344–349. 48 indexed citations

12.

Aerts, Johannes M. F. G., Rolf G. Boot, G. Herma Renkema, et al.. (1995). Molecular and biochemical abnormalities of Gaucher disease. Chitotriosidase, a newly identified biochemical marker.. Pure Amsterdam UMC. 5 indexed citations

13.

Weely, Sonja van, et al.. (1993). Demonstration of the existence of a second, non-lysosomal glucocerebrosidase that is not deficient in Gaucher disease. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1181(1). 55–62. 108 indexed citations

14.

Weely, Sonja van, Ineke D.C. Jansen, Elisabeth M. Brouwer-Kelder, et al.. (1991). Clinical phenotype of Gaucher disease in relation to properties of mutant glucocerebrosidase in cultured fibroblasts. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1096(4). 301–311. 44 indexed citations

15.

Aerts, Johannes M. F. G., Clara Sá-Miranda, Lúcia Lacerda, et al.. (1991). The identification of type 1 Gaucher disease patients, asymptomatic cases and carriers in The Netherlands using urine samples: An evaluation. Clinica Chimica Acta. 203(2-3). 349–361. 3 indexed citations

16.

Sá-Miranda, Clara, Johannes M. F. G. Aerts, Rui Pinto, et al.. (1990). Activity of glucocerebrosidase in extracts of different cell types from type 1 Gaucher disease patients. Clinical Genetics. 38(3). 218–227. 22 indexed citations

17.

Weely, Sonja van, Johannes M. F. G. Aerts, Wilma E. Donker‐Koopman, et al.. (1990). Function of oligosaccharide modification in glucocerebrosidase, a membrane‐associated lysosomal hydrolase. European Journal of Biochemistry. 191(3). 669–677. 35 indexed citations

18.

Aerts, Johannes M. F. G., et al.. (1990). Conditions affecting the activity of glucocerebrosidase purified fom spleens of control subjects and patients with type 1 Gaucher disease. Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology. 1041(1). 55–63. 18 indexed citations

19.

Aerts, Johannes M. F. G., AndréW. Schram, Anneke Strijland, et al.. (1988). Glucocerebrosidase, a lysosomal enzyme that does not undergo oligosaccharide phosphorylation. Biochimica et Biophysica Acta (BBA) - General Subjects. 964(3). 303–308. 52 indexed citations

20.

Weely, Sonja van, et al.. (1983). Chalcone isomerase in flowers of mutants of Petunia hybrida. Planta. 159(3). 226–230. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact